| Literature DB >> 30153686 |
Jaume Capdevila1, Lisa Bodei2, Philippa Davies3, Vera Gorbounova4, Robert T Jensen5, Ulrich P Knigge6, Guenter J Krejs7, Eric Krenning8, Juan Manuel O'Connor9, Marc Peeters10, Guido Rindi11, Ramon Salazar12, Marie-Pierre Vullierme13, Marianne E Pavel14.
Abstract
Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy. ©2018 S. Karger AG, Basel.Entities:
Keywords: Biomarkers; Imaging; Metastasis; Neuroendocrine neoplasms; Therapy; Unmet medical needs
Year: 2018 PMID: 30153686 DOI: 10.1159/000493319
Source DB: PubMed Journal: Neuroendocrinology ISSN: 0028-3835 Impact factor: 4.914